UniPharma Co., Ltd. (TPEX:6621)

Market Cap	452.64M -18.0%
Revenue (ttm)	88.44M -5.4%
Net Income	-40.54M
EPS	-1.14
Shares Out	35.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	96,433
Open	13.20
Previous Close	12.75
Day's Range	12.15 - 13.20
52-Week Range	11.40 - 16.25
Beta	-0.14
RSI	34.43
Earnings Date	May 20, 2026

About UniPharma

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves m...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 31
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6621

Financial Performance

In 2025, UniPharma's revenue was 88.44 million, a decrease of -5.36% compared to the previous year's 93.46 million. Losses were -40.54 million, 63.4% more than in 2024.